Biopharmaceutical
Biotechnology
Cancer Prevention
Geron
$1.529876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.02 (1.32%) Today
-$0.02 (-1.30%) After Hours
Why Robinhood?
You can buy or sell Geron and other stocks, options, ETFs, and crypto commission-free!
About
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Read More The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
Employees
17
Headquarters
Menlo Park, California
Founded
1990
Market Cap
283.34M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
5.00M
High Today
$1.55
Low Today
$1.52
Open Price
$1.52
Volume
623.80K
52 Week High
$6.99
52 Week Low
$0.9547
Collections
Biopharmaceutical
Biotechnology
Cancer Prevention
Pharmaceutical
Health
Medical
Technology
News
Seeking AlphaMay 16
Geron Corporation Imeteslstat Program Update Call Transcript
Geron Corporation. (NASDAQ:GERN) Imeteslstat Program Update Call May 16, 2019 9:00 AM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Andrew Grethlein - Chief Operating Officer Aleksandra Rizo - Chief Medical Officer. Conference Call Participants Chad Messer - Needham & Company Tom Shrader - BTIG George Zavoico - B. Riley FBR Operator Good day, ladies and gentlemen and welcome to Geron’s Imetelstat Program Updat...
Seeking AlphaMay 16
Geron down 6% on extended timeline for imetelstat in myelofibrosis
Geron (GERN -5.9% ) slips on below-average volume in apparent response to its revised development timeline for imetelstat in myelofibrosis.
Yahoo FinanceMay 16
Geron Provides Imetelstat Program Update
Conference Call Scheduled for 9:00 a.m. ET today MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good start with the imetelstat IND transfer now complete, enabling us to move forward with the planned opening of the Phase 3 clinical trial in lower risk myelodysplastic syndromes for screening and enrollment, which we continue to expect by mid-year 2019,” said John A. Scarle...
Price Paid on Robinhood
35% Lower
Right Now
52 Week Low
$0.9547
Average Price Paid
$2.35
52 Week High
$6.99
Earnings
-$0.05
-$0.04
-$0.04
-$0.03
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 30, After Hours